





Blood 142 (2023) 3476-3478

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

704.CELLULAR IMMUNOTHERAPIES: EARLY PHASE AND INVESTIGATIONAL THERAPIES

Long Term Follow-up after Treatment with Allogeneic Off-the-Shelf CAR T Cell Therapy for Relapsed or Refractory **B-Cell Malignancies**

Sanam Shahid, MD¹, Georgia C Flynn¹, Audrey Mauguen, PhD², Jennifer Bieler¹, Susan E Prockop, MD³, Andromachi Scaradavou, MD¹, Jaap Jan Boelens, MD¹, Craig S Sauter, MD⁴, Miguel-Angel Perales, MD⁵, Sergio A. Giralt, MD FACP⁶, Xiuyan Wang, PhD⁷, Isabelle Riviere, PhD⁸, Michel Sadelain, MDPhD⁹, Renier Brentjens, MDPhD¹⁰, Nancy A Kernan, MD¹, Richard J O'Reilly, MD¹, Kevin J Curran, MD¹

CART cells provide benefit in patients with relapsed/refractory (R/R) hematologic malignancies. However, limitations of autologous products include cost, production complexity, quality of T cells, and life-threatening toxicity. To overcome these limitations, we developed allogeneic, "off-the-shelf" CD19-specific CART cells by transducing our institutional second-generation CD28-containing CAR (19-28z) into Epstein-Barr Virus (EBV)-specific cytotoxic lymphocytes (19-28z CAR EBV-CTLs).

Patients with R/R B-cell malignancies were stratified into 3 treatment cohorts: cohort 1 (disease recurrence after allogeneic or autologous hematopoietic cell transplant (HCT)), cohort 2 (19-28z CAR EBV-CTLs as consolidative therapy after autologous HCT), or cohort 3 (19-28z CAR EBV-CTLs as consolidative therapy after allogeneic HCT). The objectives were determining dose limiting toxicity (DLT; primary endpoint) and optimal dose for multiple infusions.

Sixteen patients were treated with 19-28z CAR EBV-CTLs with 8 in cohort 1 (B-ALL n=6; Burkitt lymphoma n=1; CLL n=1), 6 in cohort 2 (PMBCL n=2; DLBCL n=3; marginal zone lymphoma n=1), and 2 in cohort 3 (DLBCL n=2). Median age at treatment was 30 years (range 1-71 years). All patients were heavily pretreated, receiving a median of 5 lines of therapy (including any HCT received; range 3-11 lines of therapy) prior to 19-28z CAR EBV-CTLs. Dosing on this protocol was based off T cells/kg: median dose infused was 3x10 ⁶ T cells/kg (range 1-10x10 ⁶ T cells/kg). Twelve patients received multiple doses (overall median 2.5; range 1-3) with 3x10 ⁶ T cells/kg determined to be the optimal dose enabling multiple treatments per manufactured cell line. Products had variable transduction efficiencies with a median of 28.7% (range 7.4-41%), and median 19-28z CAR EBV-CTL dose was 0.7x10 ⁶/kg (range 0.05-2.7x10 ⁶/kg). 19-28z CAR EBV-CTL sources were primary HCT donors (n=4) and third-party donors (n=12). HLA matching between patients and donors was 10/10 (n=3), 6/10 (n=2), 5/10 (n=1), 4/10 (n=3), and 2/10 (n=7). Ten of the patients were EBV-seropositive, four were seronegative, and two were serostatus unknown.

Severe cytokine release syndrome (CRS) or neurotoxicity did not occur post-infusion, and no DLT was noted in the trial. Six patients developed diffuse skin rash with 3 patients' rashes deemed to be graft-versus-host disease (n=1 HLA-matched HCT donor; n=2 third-party donor), which resolved with topical steroids (n=3). Median follow-up was 53.3 months (range 4.2-135 months) with 4 deaths due to disease progression. Overall survival of all patients was 81% at 12 months and 74% at 24 months (Figure 1).

In summation, we successfully treated 16 patients with an allogeneic, "off-the-shelf" 19-28z CAR EBV-CTL product without significant toxicity. The manufacturing platform effectively overcomes many of the limitations of autologous CART cell products including cost, need for patient-specific manufacturing, and life-threatening toxicity. CAR EBV-CTLs also broaden the applicability of CART cell therapy for patients with insufficient circulating T cells to generate autologous products. This trial

¹ Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY

²Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

³ Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA

⁴Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

⁵ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New

⁶ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

 $^{^7}$ Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY

⁸ Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY

⁹Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY

¹⁰Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

POSTER ABSTRACTS Session 704

determined an optimal manufacturing dose of allogeneic CAR T cells to enable repeated dosing. In the cohort of heavily pre-treated patients, long-term outcomes following multiple infusions of 19-28z CAR EBV-CTLs were excellent. Allogeneic, "off-the-shelf" CAR EBV-CTLs provide a readily available therapy for patients with limited therapeutic options, and this trial demonstrates the safety of CAR T cell infusions as consolidation after HCT. This trial was registered at www.clinicaltrials.gov as NCT01430390.

Figure 1: Overall survival following 19-28z CAR EBV-CTLs of all patients by disease (A) and donor source (B).

Disclosures Prockop: AlloVir: Research Funding; Atara: Research Funding; Jasper: Research Funding; Pierre Fabre: Consultancy; CellEvolve: Consultancy; VOR: Consultancy; Regeneron: Honoraria. Boelens: Advanced Clinical: Honoraria; Immusoft: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Sobi: Consultancy, Honoraria; Omeros: Consultancy, Honoraria; Bluerock: Consultancy, Honoraria; Bluebird Bio: Honoraria; SmartImmune: Consultancy, Honoraria. Sauter: Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK.: Consultancy; Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA.: Research Funding. Perales: Adicet: Honoraria; Equillium: Consultancy, Honoraria; Omeros: Consultancy, Current equity holder in publicly-traded company, Honoraria; Kite: Consultancy, Honoraria, Research Funding; DSMB: Other; Orcabio: Consultancy, Current equity holder in publicly-traded company, Honoraria; Takeda: Consultancy, Honoraria; Incyte: Consultancy, Honoraria, Research Funding; Cidara Therapeutics: Consultancy, Other; Exevir: Consultancy, Honoraria; MorphoSys: Consultancy, Honoraria; Celgene: Honoraria; Syncopation: Honoraria; Miltenyi Biotec: Consultancy, Honoraria, Research Funding; VectivBio AG: Consultancy, Honoraria; Medigene: Consultancy, Other; NexImmune: Consultancy, Current equity holder in publicly-traded company; Miltenyi Biotec: Honoraria; Nektar Therapeutics: Consultancy, Honoraria, Research Funding; Allovir: Consultancy; Servier: Other; Karyopharm: Consultancy, Honoraria; Sellas Life Sciences: Consultancy, Astellas: Consultancy, Honoraria; Vor Biopharma: Consultancy, Honoraria; Merck: Consultancy, Honoraria; Caribou: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Allogene: Research Funding; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding. Giralt: Amgen, Actinuum, Celgene/BMS, Kite Pharma, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Spectrum Pharma, Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen, Actinuum, Celgene/BMS, Omeros, Johnson & Johnson, Miltenyi, Takeda: Research Funding. Riviere: Takeda: Current Employment. Sadelain: Mnemo: Current equity holder in private company, Research Funding; Minerva: Current equity holder in private company; Takeda: Research Funding; Fate: Research Funding; Atara: Research Funding. Brentjens: R.J.B. has licensed intellectual property to and collect royalties from BMS, Caribou and Sanofi. R.J.B. received research funding from BMS. R.J.B. is a consultant to BMS, Atara Biotherapeutics Inc, Coimmune, Triumvira and was a consultant for Gracell Bi: Consultancy, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: BMS, Caribou and Sanofi, Research Funding. Kernan: Amgen: Current equity holder in publicly-traded company; Pfizer: Current equity holder in publicly-traded company; Merck: Current equity holder in publicly-traded company; Johnson and Johnson: Current equity holder in publicly-traded company. O'Reilly: Atara Biotherapeutics: Consultancy, Patents & Royalties, Research Funding. Curran: Novartis: Consultancy, Research Funding; Celgene: Research Funding; Cellectis: Research Funding; Atara: Consultancy, Research Funding; Turn Bio: Consultancy.

https://doi.org/10.1182/blood-2023-180753




Figure 1